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Abstract: 
The international federation state that, 415 million people have diabetes, in which 91% have type 2 diabetes 
(T2DM). The overall world’s population suffering from type 2 diabetes is 8.8% that too would rise to 642 million by 
2040.  Prevalence of type 2 diabetes mellitus has been increasing quickly with the passage of time. A study 
conducted by Abraham et al report that the incidence of the diabetes is 83.3% and higher in males than females.  
Cardiovascular disease is one of the major cause of death and causing disability among people suffering from 
diabetes. Adults who have diabetes have more prevalence of CVD as compared to adults without diabetes. And the 
risk of developing CVD increases continuously with rising fasting plasma glucose level. T2DM decreases the life 
expectancy by 10 years and one of the leading causes to death is CVD. Moreover, people with T2DM are more 
prone to develop CVD than no diabetic people. A study conducted to calculate the death rates due to cardiovascular 
disease over 7 year period in patient with and without type 2 diabetes. 
CVD is one of the major cause of death in T2DM with coronary artery disease having the high prevalence. 
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INTRODUCTION: 
The international federation state that, 415 million 
people have diabetes, in which 91% have type 2 
diabetes (T2DM). The overall world’s population 
suffering from type 2 diabetes is 8.8% that too would 
rise to 642 million by 2040 [1].  Prevalence of type 2 
diabetes mellitus has been increasing quickly with the 
passage of time. A study conducted by Abraham et al 
report that the incidence of the diabetes is 83.3% and 
higher in males than females [2].  Cardiovascular 
disease is one of the major cause of death and 
causing disability among people suffering from 
diabetes [3]. Adults who have diabetes have more 
prevalence of CVD as compared to adults without 
diabetes [4]. And the risk of developing CVD 
increases continuously with rising fasting plasma 
glucose level [5]. T2DM decreases the life 
expectancy by 10 years and one of the leading causes 
to death is CVD. Moreover people with T2DM are 
more prone to develop CVD than no diabetic people. 
A study conducted to calculate the death rates due to 
cardiovascular disease over 7 year period in patient 
with and without type 2 diabetes. 
People who had T2DM, the death rates were 15.4% 
to those who previously had no history of MI and 
42.0% in patients having history of MI where as in 
patients who had no diabetes, the death rate were 
2.1% and 15.9% respectively [6].  Literatures showed 
that the prevalence of T2DM is increasing along with 
the risk of CVD.  The risks of having CVD in 1952-
1974 were 5.4% whereas in 1975 the risks were 
increased to 8.7% [7]. 
Another longitudinal study conducted on 881 patients 
with T2DM over 10 years, conclude that ratio due to 
CVD constantly increasing each year [8] the clinical 
burden that CVD complications have on T2DM, the 
focus on the joint management has been increased. 
Plasma glucose level control is the main management 
in T2DM to protect the micro vascular complications 
and CVD [9] [10]. its role has not been yet cleared in 
T2DM. [11][12][13]. to prevent micro vascular 
complications other risk factors must be under 
consideration. There must be reduction in glucose 
level, smoking cessation, diet, exercise, blood 
pressure, and plasma lipid level. There are so many 
treatment guidelines present to prevent the onset of 
CVD [14]. There are sverl treatment to reduce CVD 
in non-diabetic people specially to prevent major 
events such as non-fatal MO, stroke etc[15] [16]  
Following these regulatory requirements, several 
cardiovascular outcomes trials (CVOT) have been 
completed, which demonstrate that certain anti-
diabetic treatments are associated with a lower risk of 
CVD [17-20].   
CVD includes coronary artery disease (CAD), 
cerebrovascular disease (CBV), and peripheral 
vascular disease, the focus of this review was on 
CVD outcomes that are relevant to major 
cardiovascular events. Therefore, the review 
specifically focused on the prevalence of CAD and 
CBV. CAD has many synonyms, including ischemic 
heart disease, coronary heart disease (CHD), 
atherosclerotic heart disease, and atherosclerotic 
CVD. Conditions within this category are stable 
angina pectoris, unstable angina pectoris, MI (also 
known as heart attack), and sudden cardiac death 
(SCD).  
METHODS: 
This study was based on systematic review. 57 
articles were reviewed. All the participants’ age more 
than 18 having diabetes were included in this study.  
Prevalence rates were compared between male and 
female and between obese and no-obese patient. All 
the participants who previously had peripheral artery 
disease (PAD), rheumatic heart disease, cardiac 
dysrhythmias (e.g., atrial or ventricular fbrillation), or 
requirement for surgery such as coronary artery 
bypass grafting (CABG)/coronary revascularization 
were excluded.  
 
Obese versus non obese and males versus females: 
About half of the patients included in this study had 
obesity. The most commonly used definition of 
obesity was a BMI≥30 kg/m2. Literature reported 
that prevalence rates of CVD according to obesity, 
and found a positive relationship between obesity and 
increased prevalence rates of CVD.A study 
conducted by Bhatti et  al found a positive correlation 
between obesity and CAD (P=0.021). [21][22][23] 
 
Tamba et  al. reported positive correlations between 
obesity and both CAD and stroke [24]. Boonman-de 
Winter et  all quantifed the relationship between BMI 
and heart failure. The prevalence rate of heart failure 
was 38.7% (95% CI 31.2–46.1%) in patients with a 
BMI ≥ 30  kg/m2 and 23.4% (95% CI 19.4–27.5%) 
in those with a BMI < 30  kg/m2 , which represents a 
65% increase due to obesity [25] 
Studies explored the relationship between increasing 
BMI and risk of CVD. According to Wentworth et al, 
for CAD in both males and females, the prevalence 
rate of CAD increased with each successive increase 
in BMI, with a five-fold increase between the lowest 
and highest categories [40  kg/m2 (severe obesity) 
[26]  
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The difference was that prevalence rates in males 
were about double those for females in every BMI 
category. For the outcome stroke/transient ischemic 
attack (TIA) in males, only the highest category 
(BMI>40) had elevated prevalence rates, which were 
about double those for the lowest category (BMI For 
females, prevalence rates of stroke/TIA increased in 
those who were overweight and had mild or moderate 
obesity but decreased for those with severe obesity. 
Finally, Glogner et al. had quite different results. 
They reported a steady increase in prevalence rates of 
MI from 6.86% in those with a BMI category of 
obesity. The highest category (BMI≥40) had a 
prevalence rate of 5.01%, which was 27% lower than 
those in the lowest category (BMI ≥40 ) had a 
prevalence rate of 5.01%, which was 27% lower than 
those in the lowest category Thus, patterns vary quite 
widely, and studies often examined different 
outcomes [27][28] 
DISCUSSION: 
The overall estimated result of prevalence of CVD in 
T2DM was 32.2%. One of the most common type of 
CVD was coronary artery disease and rarest was 
stroke 7.6%. Males were more prone to prevalent 
diseases than females. CAD was the leading factor of 
death in T2DM. Together with CVD age and obesity 
are major risk factors. 
Age as a risk factor 
Age is a well-defined risk factor for CVD. Some 
studies support this idea whereas some might not.  
Alonso-Moran state that the risk of having MI, 
stroke, heart failure increased with the increase in 5 
year category as compared with age group 35-39 
used as reference [29]. Another study similarly report 
that the prevalence of heart failure increase with the 
increase of age [30].  Studies have reported that 
younger patients have less prevalence rates than older 
patients but they gave not given any age category to 
relate [31]. Whereas some studies have reported that 
there is no relation between age categories [32]. 
Obesity: 
Obesity is an independent risk factor for CVD and 
strongly linked with coronary artery disease, 
atherosclerosis, and cardiac failure [33]. The 
prevalence of T2DM has been seen in overweight 
and obese patients; moreover they are more prone to 
develop cardiovascular diseases [34]. Obesity is 
defined according to WHO, adult having BMI 
30lg/m2 as obese. Therefore BMI measure is to warn 
people about their risk of having obese which is 
associated with so many risk factors [35] 
 
Seven studies investigated the relationship of obesity 
and CVD risk. Five of them showed the direct 
relation between obesity and and high prevalence of 
CVD [36].  
One of these studies used lower BMI cut-of points to 
account for Asian populations in accordance with 
WHO recommendations on BMI for Asian 
populations and evaluated abdominal adiposity with 
waist circumference measurements to determine the 
prevalence of obesity [37]. Overall, the studies found 
a positive relationship between increasing BMI and 
CVD; except in one study, where women with severe 
obesity had a reduced prevalence of stroke [38] 
While the authors do not explain the reduced 
prevalence of stroke/ TIA, it may be explained by 
diferences in vascular risk markers in men, such as 
pre-existing ischemic heart disease, age, and smoking 
[40]. Furthermore, the presence of gonadal steroids, 
most notably estrogen, may lend a protective efect 
against stroke/TIA in women and it has been shown 
that adiposity is associated with increased levels of 
estrogen. Although obesity is identifed as a risk 
factor for CVD, it is associated with a paradox in that 
mortality is lower in patients who are overweight or 
obese than in those whose BMI is normal or 
underweight [41]. Lee et  al. reported that obesity 
provided a survival beneft to patients with heart 
failure who did not have comorbid diabetes, but not 
in patients who did have concomitant diabetes. In 
contrast, a group led by Abi Khalil examined a cohort 
of 2492 T2DM patients in seven countries in the 
Middle East, Gulf region, with acute heart failure 
[42] 
CONCLUSION: 
CVD is one of the major cause of death in T2DM 
with coronary artery disease having the high 
prevalence. 
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